WilmerHale Advises Generation Bio in Initial Public Offering

WilmerHale Advises Generation Bio in Initial Public Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On June 16, 2020, Generation Bio, an innovative genetic medicines company creating a new class of gene therapy, announced the closing of its initial public offering. The company sold 12,105,263 shares of its common stock at a public offering price of $19.00 per share, reflecting the full exercise of the underwriters’ option to purchase additional shares, for aggregate gross proceeds of approximately $230 million, before deducting underwriting discounts and commissions and estimated offering expenses. The shares are listed on the Nasdaq Global Select Market (GBIO). J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company LLC acted as joint book running managers and Wedbush PacGrow acted as lead manager of the offering.

The deal team representing Generation Bio was led by Stuart Falber and Molly Fox.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel